- Home
- CAPR vs NATR Comparison
CAPR vs NATR Comparison
Compare CAPR & NATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- NATR
- Stock Information
- Founded
- CAPR 2005
- NATR 1972
- Country
- CAPR United States
- NATR United States
- Employees
- CAPR N/A
- NATR N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- NATR Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- NATR Health Care
- Exchange
- CAPR Nasdaq
- NATR Nasdaq
- Market Cap
- CAPR 324.6M
- NATR 297.2M
- IPO Year
- CAPR N/A
- NATR N/A
- Fundamental
- Price
- CAPR $6.92
- NATR $13.42
- Analyst Decision
- CAPR Strong Buy
- NATR Strong Buy
- Analyst Count
- CAPR 6
- NATR 2
- Target Price
- CAPR $23.00
- NATR $20.50
- AVG Volume (30 Days)
- CAPR 1.1M
- NATR 66.7K
- Earning Date
- CAPR 11-11-2025
- NATR 11-06-2025
- Dividend Yield
- CAPR N/A
- NATR N/A
- EPS Growth
- CAPR N/A
- NATR N/A
- EPS
- CAPR N/A
- NATR 0.75
- Revenue
- CAPR $13,392,150.00
- NATR $460,818,000.00
- Revenue This Year
- CAPR N/A
- NATR $4.88
- Revenue Next Year
- CAPR $7,894.07
- NATR $2.66
- P/E Ratio
- CAPR N/A
- NATR $17.92
- Revenue Growth
- CAPR N/A
- NATR 4.33
- 52 Week Low
- CAPR $5.68
- NATR $11.01
- 52 Week High
- CAPR $22.90
- NATR $18.06
- Technical
- Relative Strength Index (RSI)
- CAPR 53.74
- NATR 25.90
- Support Level
- CAPR $6.05
- NATR $13.97
- Resistance Level
- CAPR $6.42
- NATR $14.49
- Average True Range (ATR)
- CAPR 0.39
- NATR 0.43
- MACD
- CAPR -0.01
- NATR -0.05
- Stochastic Oscillator
- CAPR 56.28
- NATR 6.90
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.